

APPLIED GENETIC TECHNOLOGIES CORP  
Form 8-K  
July 13, 2016

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): July 7, 2016**

**APPLIED GENETIC TECHNOLOGIES CORPORATION**

*(Exact Name of Registrant as Specified in Charter)*

**Delaware**  
*(State or other jurisdiction  
of incorporation)*

**001-36370**  
*(Commission  
File Number)*

**59-3553710**  
*(IRS Employer  
Identification Number)*

**14193 NW 119<sup>th</sup> Terrace**

**Suite 10**

**Alachua, Florida 32615**

*(Address of principal executive offices) (Zip Code)*

**(386) 462-2204**

*(Registrant's telephone number, including area code)*

**Not Applicable**

*(Former Name or Former Address, if Changed Since Last Report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 8-K

- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e)

On July 7, 2016, the compensation committee of our board of directors approved salary increases for fiscal year 2017 for Susan Washer, our president and chief executive officer, Lawrence Bullock, our chief financial officer, Jeffrey Chulay, our vice president and chief medical officer, Stephen Potter, our vice president and chief business officer, and Mark Shearman, our chief scientific officer. The following table sets forth for each individual their salary for fiscal year 2017.

<b>Name</b>	<b>Fiscal Year 2017 Salary</b>	
Susan Washer	\$	487,000
Lawrence Bullock	\$	341,000
Jeffrey Chulay	\$	400,000
Stephen Potter	\$	331,000
Mark Shearman	\$	370,000

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**APPLIED GENETIC TECHNOLOGIES  
CORPORATION**

By: /s/ Lawrence E. Bullock  
Lawrence E. Bullock

Chief Financial Officer

Date: July 13, 2016